While the study described here was restricted to ER+ tumors, we hope that this model will be extended to other molecular sub-classes of breast tumors and eventually may be used to direct individualized therapies based on inclusion of the characteristics of a patient's tumor microenvironment. This evidence concerns the gene ESR1 and neoplasm.